2023
Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
Hudson J, Cruickshank M, Quinton R, Aucott L, Wu F, Grossmann M, Bhasin S, Snyder P, Ellenberg S, Travison T, Brock G, Gianatti E, van der Schouw Y, Emmelot-Vonk M, Giltay E, Hackett G, Ramachandran S, Svartberg J, Hildreth K, Antonic K, Tenover J, Tan H, Ho Chee Kong C, Tan W, Marks L, Ross R, Schwartz R, Manson P, Roberts S, Skovsager Andersen M, Velling Magnussen L, Aceves-Martins M, Gillies K, Hernández R, Oliver N, Dhillo W, Bhattacharya S, Brazzelli M, Jayasena C. Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis. The Lancet Healthy Longevity 2023, 4: e561-e572. PMID: 37804846, DOI: 10.1016/s2666-7568(23)00169-1.Peer-Reviewed Original ResearchConceptsBenefits of testosterone treatmentData meta-analysisParticipant data meta-analysisSerum total testosteroneBaseline serum total testosteroneMild erectile dysfunctionTestosterone treatmentParticipant dataMeta-analysisPatient ageIIEF-15Sexual functionTotal testosteroneErectile dysfunctionSymptomatic benefitLow testosteroneSerum total testosterone concentrationsAging Male Symptoms ScoreSystematic reviewBaseline serum testosteroneHealth Technology Assessment programmeOlder menIIEF-15 scoreTestosterone replacement therapyMinimal clinically important differenceRobot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials
Khetrapal P, Wong J, Tan W, Rupasinghe T, Tan W, Williams S, Boorjian S, Wijburg C, Parekh D, Wiklund P, Vasdev N, Khan M, Guru K, Catto J, Kelly J. Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials. European Urology 2023, 84: 393-405. PMID: 37169638, DOI: 10.1016/j.eururo.2023.04.004.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyOpen radical cystectomyRadical cystectomyBlood lossThromboembolic eventsAssociated with better physical functionBladder cancerPositive surgical margin rateAssociated with more blood lossRisk of thromboembolic eventsHealth-related QoLQuality of life outcomesProgression-free survivalSurgical margin rateLymph node yieldRobot-assisted approachShorter operative timeShorter hospital lengthQuality of lifeRandomized controlled trialsSystematic literature searchPhysical functionWeb of ScienceNode yieldOverall survival
2021
Recovery of health‐related quality of life in patients undergoing robot‐assisted radical cystectomy with intracorporeal diversion
Abozaid M, Tan W, Khetrapal P, Baker H, Duncan J, Sridhar A, Briggs T, Selim M, Abdallah M, Elmahdy A, Elserafy F, Kelly J. Recovery of health‐related quality of life in patients undergoing robot‐assisted radical cystectomy with intracorporeal diversion. BJU International 2021, 129: 72-79. PMID: 34092021, DOI: 10.1111/bju.15505.Peer-Reviewed Original ResearchConceptsGlobal HRQoL scoreHealth-related quality of lifeRobot-assisted radical cystectomyEORTC QLQ-C30HRQoL scoresQuality of lifeSexual functionRadical cystectomyUrinary diversionIleal conduitIC patientsRecovery of health-related quality of lifeFunction scoresClavien-Dindo complicationsHealth-related qualityPhysical function scoresRehabilitation of sexual functionIntracorporeal urinary diversionLongitudinal analysisSexual function scoresEuropean Organisation for ResearchMonths follow-upEORTC QLQ-BLM30Higher sexual function scoresReturn to baseline
2020
Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach
Tan W, Teo C, Chan D, Ang K, Heinrich M, Feber A, Sarpong R, Williams N, Brew‐Graves C, Ng C, Kelly J, Khetrapal P, Sridhar A, Baker H, Ocampo F, Whotton N, Dent K, Pearson S, Hatton J, Newton M, Heeney E, Green K, Evans S, Rogers M, Dann A, Cook J, Cornwell M, Mills R, Knight H, Maher S, Rane A, Thomas S, Reyner S, Vallejera G, Adeniran P, Masood S, Ridgway S, Coulding M, Savill H, Mccormick J, Clark M, Collins G, Jewers K, Keith S, Bowen G, Hargreaves J, Riley K, Srirangam S, Mistry R, Chadwick J, Cocks S, Hull R, Loftus A, Dawson L, Roberts H, Main C, Jain S, Waymont C, Rogers J, Grant A, Carter V, Heap H, Lomas C, Cooke P, Baird Y, Moore S, Greenslade S, Margalef J, Chadbourn I, Harris M, Hicks J, Clitheroe P, Connolly S, Hodgkinson S, Haydock H, Sinclair A, Storr E, Cogley L, Natale S, Lovegrove W, Smith S, Smith K, Hewitt D, Sriram R, Atkinson K, Royle L, Madine J, MacLean K, Walsh J, Guerdette A, Hill M, Payne D, Power A, Cannon J, Devereaux L, Thompson A, Scarratt L, Hodgkiss T, Johnstone D, Johnson J, Allsop J, Rothwell J, Connolly K, Cherian J, Wardle H, Wilson D, Bayles A, Pelluri S, Pati J, Gherman A, Scott C, Madaan S, Taylor J, Edmunds E, Moore J, Rees A, Williams S, Caddy S, Dukes S, Goffe A, Buckhorn K, Nichols L, Acher P, Baillie K, Middleton K, Proctor C, Cresswell J, Chilvers A, Cain M, Vaux A, Watson D, Bradfield S, Gregory H, Mostafid H, Kehoe L, Drakeley S, Davies J, Williamson L, Krishnan R, Lunt N, Hill P, Burns H, Townley B, Wilkinson L, Wassall H, Sinclair A, Hunt J, Holbrook B, Stancombe L, Morrison J, Vankoutrik L, Misra S, Fossey G, Richards A, Mcdonald K, Henderson A, Fennelly R, Tribbeck M, Ames K, Borwell J, Kotze M, Beesley K, Rennie K, Porter T, Gipson A, Piper L, Bailey L, Chrisopoulou A, Slevin K, McCartin F, Warburton H, Hathaway‐Lees S, Whetton K, Delves G, Day A, Bankole T, Broadhead S, Malde S, Oblak M, Ellis D, Bishara S, Barias‐Lara T, Donkov I, Thatcher H, Morris H, Culmsee C, Menzies A, Bartlett C, Cutting C, O'Brien N, Jannapureddy R, Kelkar A, Fitzgerald J, Longhurst S, Worth C, Peracha A, Mzazi S, Poile C, Griffiths L, Cook A, Barber N, Brar N, Alty A, Zelhof B, Blades R. Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed‐methods approach. BJU International 2020, 125: 669-678. PMID: 31975539, PMCID: PMC7318301, DOI: 10.1111/bju.15008.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancer diagnosisPatient experienceNon-muscle-invasive bladder cancerTransurethral resection of bladder tumorCancer diagnosisBrief IPQMixed-methods approachBrief Illness Perception QuestionnaireCause of bladder cancerRisk of bladder cancerMental health of patientsIllness Perception QuestionnairePersonal controlBladder cancerHealth of patientsSemi-structured interviewsPerception of disease controlLow personal controlMental healthProspective multicentre observational studyPsychological supportUrine biomarker studiesPerception QuestionnaireDiagnosis of non-muscle-invasive bladder cancerPoor perception
2019
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
Cox E, Saramago P, Kelly J, Porta N, Hall E, Tan W, Sculpher M, Soares M. Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial. Clinical Genitourinary Cancer 2019, 18: e418-e442. PMID: 32144049, PMCID: PMC7427321, DOI: 10.1016/j.clgc.2019.12.004.Peer-Reviewed Original ResearchConceptsHealth-related quality of lifeNon-muscle-invasive bladder cancerMuscle-invasive bladder cancerProgression to muscle-invasive bladder cancerQuality of lifePatients' health-related quality of lifePatients' health-related qualityBladder cancerHealth-related qualityEQ-5D-3LGeneralized estimating equationsUK unit costsRandomized controlled trialsHRQoL decrementNon-muscle-invasive bladder cancer patientsHRQoLHealthcare costsHRQOL effectsLimited evidenceControlled trialsEstimating equationsTMN classificationClinical eventsAverage costRecurrence
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapy
2016
Robotic Assisted Radical Cystectomy with Extracorporeal Urinary Diversion Does Not Show a Benefit over Open Radical Cystectomy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Tan W, Khetrapal P, Tan W, Rodney S, Chau M, Kelly J. Robotic Assisted Radical Cystectomy with Extracorporeal Urinary Diversion Does Not Show a Benefit over Open Radical Cystectomy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PLOS ONE 2016, 11: e0166221. PMID: 27820855, PMCID: PMC5098822, DOI: 10.1371/journal.pone.0166221.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyOpen radical cystectomyMeta-analysis of randomised controlled trialsExtracorporeal urinary diversionRandomised controlled trialsRadical cystectomyUrinary diversionPerioperative morbidityBladder cancerLack of Level I evidenceRobot-assisted radical cystectomy groupsPositive lymph node statusOutcomes of robot-assisted radical cystectomySystematic reviewControlled trialsOpen radical cystectomy patientsEfficacy of robot-assisted radical cystectomyInclusion criteriaPositive surgical marginsLymph node statusLymph node yieldMeta-analysisLevel I evidenceIntracorporeal urinary diversionWell-designed trials